

# BCCA Protocol Summary for Palliative Therapy of Extensive Stage Small Cell Lung Cancer (SCLC) with Oral Etoposide

**Protocol Code:** *LUSCPOE*  
**Tumour Group:** *Lung*  
**Contact Physician:** *Dr. Nevin Murray*

## **ELIGIBILITY:**

- Extensive stage SCLC in patients refusing or unsuitable for combination chemotherapy
- Relapsed SCLC after prior chemotherapy with disease-free interval > 3 months

## **TESTS:**

- Baseline: CBC & differential, platelets
- Before each treatment: CBC & differential, platelets

## **PREMEDICATIONS:**

- See antiemetic guidelines for non-emetogenic chemotherapy (see protocol SCNAUSEA). Antiemetics are not usually required. Prescribe according to patient specific symptoms.

## **TREATMENT:**

<b>Drug</b>	<b>Dose</b>	<b>BCCA Administration Guidelines</b>
Etoposide	50 mg PO BID x 7 days	PO

- Repeat every 21 days x 4-6 cycles

## **DOSE MODIFICATIONS:**

### 1. Hematology

<b>ANC (x 10<sup>9</sup>/L)</b>		<b>Platelets (x 10<sup>9</sup>/L)</b>	<b>Etoposide dose</b>
Greater than or equal to 2.0	and	Greater than or equal to 100	100%
Less than 2.0	or	Less than 100	<b>Delay</b>

### 2. Neutropenic Sepsis: reassess subsequent doses

## **PRECAUTIONS:**

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

**Contact Dr. Nevin Murray or tumor group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

Date Activated:           October 1991 (as LUPOE)

Date Revised:             1 Mar 2010 (protocol code revised)

## **REFERENCES:**